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A B S T R A C T
Aims: To describe the characteristics and associated risk factors of patients with established diabetes
who required Emergency Department (ED) care for severe hypoglycemia.
Methods: We performed an observational retrospective study to identify all cases of severe hypoglyce-
mia among attendees at the EDs of three Italian University hospitals from January 2010 to December
2014.
Results: Overall, 520 patients with established diabetes were identiﬁed. Mean out-of-hospital blood glucose
concentrations at the time of the hypoglycemic event were 2.2 ± 1.3 mmol/L. Most of these patients were
frail and had multiple comorbidities. They were treated with oral hypoglycemic drugs (43.6%), insulin
(42.8%), or both (13.6%). Among the oral hypoglycemic drugs, glibenclamide (54.5%) and repaglinide (25.7%)
were the two most frequently used drugs, followed by glimepiride (11.3%) and gliclazide (7.5%). Hospi-
talization rates and in-hospital deaths occurred in 35.4% and in 2.3% of patients, respectively. Cirrhosis
(odds ratio [OR] 6.76, 95% conﬁdence interval [CI] 1.24–36.8, p < 0.05), chronic kidney disease (OR 2.42,
95% CI 1.11–8.69, p < 0.05) and center (Sapienza University OR 3.70, 95% CI 1.57–8.69, p < 0.05) were the
strongest predictors of increased rates of hospital admission.
Conclusions: Severe hypoglycemia is a remarkable burden for patients with established diabetes and in-
creases the risk of adverse clinical outcomes (in-hospital death and hospitalization), mainly in elderly
and frail patients. This study further reinforces the notion that careful attention should be taken by health
care providers when they prescribe drug therapy in elderly patients with serious comorbidities.
© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Severe hypoglycemia is deﬁned as having lowblood glucose con-
centrations that require assistance from another person to treat and
has the potential to cause accidents, injuries, coma and death [1].
Severe hypoglycemia is a relatively frequent event in patients with
established diabetes that also markedly impacts on health re-
sources [1]. It is estimated that theevent rates for severehypoglycemia
range from 115 to 320 per 100 patient/years for patients with type
1 diabetes, and from 35 to 70 per 100 patient/years for those with
type 2 diabetes [2,3]. Hypoglycemiamay be due tomultiple causes,
such as the misuse of insulin therapy, the use of oral hypoglycemic
drugs with a higher risk of hypoglycemia (e.g., sulfonylureas and
repaglinide) or the combination of multiple drugs that may inter-
act with each other, such as antibiotics and sulfonylureas [1–6].
Importantly, Leese et al. reported that the rate of severe hypogly-
cemiawas as common in patientswith type 2 diabetes treatedwith
insulin as in patients with type 1 diabetes [7].
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For the clinicians, reaching a tight glycemic control is often an
important goal to minimize the development and progression of
chronic complications in many patients with type 1 or type 2 di-
abetes but, as also highlighted by recent clinical trials, many doubts
remain regarding the ‘optimal’ glycemic targets in older patients with
type 2 diabetes [8–12]. Several international guidelines suggest that
the targets for glucose control should be less stringent in older pa-
tients with diabetes, and promote the use of oral hypoglycemic drugs
that cause less frequently hypoglycemia in this group of more vul-
nerable patients [13,14].
Moreover, it is also important to consider that the costs of severe
hypoglycemias for public health are very high, especially if we also
consider the costs arising from the use of ambulance, on-site treat-
ment, access to emergency department and admission to the hospital
[15].
Therefore, it is clinically important to identify and implement
new strategies aimed at reducing the risk of severe hypoglycemias
in patients with established diabetes. Presently, there is a paucity
of available data on the prevalence of severe hypoglycemias in pa-
tients with established diabetes attending the emergency department
(ED) [4,6].
Thus, the aim of this multicenter study was to describe the main
characteristics and the associated risk factors of patients with
established diabetes requiring ED care for severe hypoglycemia.
Materials and methods
Patients
We performed a retrospective multicenter study identifying all
cases of severe hypoglycemia among patients with established di-
abetes, who attended the ED of three Italian University Hospitals
(‘Sapienza’ University of Rome, ‘Tor Vergata’ University of Rome, and
University and Azienda Ospedaliera Universitaria Integrata of Verona)
over the period between January 2010 and December 2014. Where
an individual had had multiple accesses in the ED for severe hy-
poglycemia during this period, only the ﬁrst access with complete
data was considered for the statistical analysis.
Initially, we electronically searched for the terms “hypoglyce-
mia” or “hypoglycemic event” in the discharge diagnosis from the
hospital, or for recorded blood glucose levels less than 3.8 mmol/L
(<70 mg/dL) at ED admission, so identifying a total of 879 pa-
tients. Patients without previously known diabetes before ED
admission (n = 359) were excluded from statistical analysis. We think
the relatively high prevalence of hypoglycemic events in this sub-
group of patients without previously known diabetes was likely due
to the following two factors. Firstly, we used a threshold of
3.8 mmol/L (<70 mg/dL) to identify any hypoglycemic events with
a possible overestimation of the events. Secondly, as reported in
Supplemental Table S1, there was a high prevalence of cirrhosis and
cancer (i.e., two diseases known to cause mild-to-moderate
hypoglycemias) among patients attending the ED of Sapienza Uni-
versity, a hospital where many patients, who are in liver transplant
list, come to get the cure.
As a result of this selection, 520 (286 men and 234 women) pa-
tients with established diabetes were included in ﬁnal analysis. The
diagnosis of the type of diabetes was made according to what re-
ported on the ED’s electronic records and then conﬁrmed by the
diabetes registers when available (Verona University). A ﬂow chart
of the study is summarized in Fig. 1.
The ethics committees of the three University hospitals ap-
proved the study protocol. The informed consent requirement for
the study was exempted by the ethics committee, because research-
ers only accessed retrospectively a de-identiﬁed database for analysis
purposes.
Data collection
Information on age, sex, type of diabetes, blood glucose con-
centrations at the time of the hypoglycemic event (measured at home
and/or by the ambulance staff), blood glucose concentrations mea-
sured in EDs, use of anymedications (including hypoglycemic drugs),
alcohol abuse, emergency codes given at the triage, and rates of hos-
pital admission and in-hospital mortality were extracted by the ED’s
electronic databases. Information on ambulance calls, falls and coma
(using the Glasgow Coma Scale) was also extracted by the elec-
tronic databases.
Information on main comorbidities was also recorded for all pa-
tients. Presence of cardiovascular diseases was deﬁned as a prior
diagnosis of ischemic heart disease or ischemic stroke; arrhyth-
mias included a history of any disturbance of cardiac rhythm or use
of antiarrhythmic drugs; chronic kidney disease (CKD) included any
diagnosis of moderate-to-severe chronic renal failure (deﬁned as
an eGFRMDRD <60 or <30 mL/min/1.73 m2, respectively) and/or di-
alysis; chronic liver diseases were limited to a prior diagnosis of
cirrhosis of any etiology; cancer included both solid and blood ma-
lignancies; ﬁnally, the presence of a prior history of dementia
included any diagnosis of cognitive impairment.
Statistical analysis
Data are presented as means ± standard deviation (SD), medians
(interquartile range, IQR) or percentages. Skewed variables (i.e., serum
creatinine and alanine aminotransferase levels) were logarithmi-
cally transformed to improve normality prior to analysis. The one-
way ANOVA test (for continuous variables) and the chi-squared test
(for categorical variables) were used to compare the clinical and bio-
chemical characteristics of patients with diabetes stratiﬁed either
by the type of treatment (secretagogues alone [i.e., glibenclamide,
glimepiride, gliclazide, repaglinide], insulin alone, or insulin plus
secretagogues) or by the three participating EDs (see Fig. 3 and
Supplemental Table S1, respectively). Univariate logistic regres-
sion analysis was used to examine the risk factors associated with
subsequent hospital admission, which was included as the depen-
dent variable. Subsequently, we performed a multivariate logistic
regression analysis that included as covariates all signiﬁcant
Figure 1. Details of the study design.
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predictors in the univariate analysis (Table 2). We also repeated all
these analyses separately in patients with type 1 diabetes and in
those with type 2 diabetes (Table 2).
A p-value <0.05 was considered to be statistically signiﬁcant. Sta-
tistical analyses were performed using SPSS software, version 22.0
(IBM Corp, Armonk, NY).
Results
Baseline clinical and biochemical characteristics of patients
Of the 520 patients with established diabetes included in the
study, 444 (85.4%) patients had type 2 diabetes, 68 (13.1%) had type
1 diabetes and the remaining 8 patients had diabetes due to other
secondary causes.
Table 1 shows the main clinical and biochemical characteris-
tics of the study participants. Overall, 332 (55%) were male and their
mean age was 72 years. Mean out-of-hospital blood glucose con-
centrations at the time of the hypoglycemic event (measured at home
and/or by the ambulance staff) were 2.2 ± 1.3 mmol/L. Conversely,
blood glucose concentrationsmeasured in the ED’s laboratories were
4.2 ± 2.8 mmol/L.
Most patients had one or more co-morbidities, such as isch-
emic heart disease (occurring in 30.1% of cases), cancer (14.4%),
cirrhosis (6.8%), dementia (12.3%), arrhythmias (9.0%), chronic ob-
structive pulmonary disease (15.0%) or end-stage renal disease (4.8%).
Table 1
Main clinical and biochemical characteristics of patients with established diabetes attending the emergency department (ED) for severe hypoglycemia
Characteristics Overall
(n = 520)
Patients with
T1DM (n = 68)
Patients with
T2DM (n = 444)
Male sex (n, %) 286 (55%) 64% 54%
Age (years) 72 ± 16 43 ± 18 75 ± 13
Type of diabetes (n, %)
Type 1 68 (13.1%) 68 (100%) 0
Type 2 444 (85.4%) 0 444 (100%)
Others 8 (1.5%) 0 0
Diabetes duration (years) 22 ± 11 25 ± 10 21 ± 8
Out-of-hospital blood glucose (mmol/L) 2.2 ± 1.3 2.1 ± 0.8 2.2 ± 0.9
Blood glucose recorded in ED (mmol/L) 4.2 ± 2.8 5.0 ± 4.1 4.0 ± 2.6
Glucose stick recorded in ED (mmol/L) 4.8 ± 3.0 5.6 ± 3.5 4.7 ± 2.9
Hemoglobin (g/L) 122 ± 19 141 ± 14 120 ± 19
Platelets (× 100,000/mm3) 243 ± 96 236 ± 89 245 ± 92
Creatinine (umol/L) 97 [70–158] 75 [64–87] 106 [76–158]
eGFRMDRD (mL/min/1.73 m2) 61 ± 40 93 ± 37 57 ± 39
eGFRMDRD <30 mL/min/1.73 m2 (n, %) 107 (20.6%) 4.5% 23.4%
eGFRMDRD 30–60 mL/min/1.73 m2 (n, %) 299 (57.6%) 14.7% 65.1%
ALT (U/L) 19 [13–31] 23 [17–29] 18 [12–31]
Falls at home (n, %) 90 (17.6%) 26.0% 16.4%
Ambulance calls (n, %) 384 (74.1%) 72.0% 75.6%
Medical triage code (n, %)
White/Green 83 (16.1%) 6.0% 17.8%
Yellow 374 (72.3%) 90.0% 68.7%
Red 60 (11.6%) 4.0% 12.8%
Glasgow coma scale (n, %)
>7 351 (96.2%) 97.4% 62.4%
≤7 14 (3.8%) 2.6% 2.7%
One oral glucose-lowering agent users (n, %) 99 (19.1%) 0% 22.3%
Two oral glucose-lowering agents users (n, %) 118 (22.8%) 0% 26.5%
Three oral glucose-lowering agents users (n, %) 9 (1.7%) 0% 20.3%
Insulin users (n, %) 223 (42.8%) 100% 34.9%
Combination therapy users (n, %) 71 (13.6%) 0% 15.9%
Statin users (n, %) 164 (33.0%) 19.3% 34.0%
Anti-platelet drug users (n, %) 219 (44.1%) 18.7% 46.3%
Anti-coagulant users (n, %) 63 (12.7%) 10.3% 12.6%
Diuretic users (n, %) 191 (38.4%) 10.0% 41.4%
Beta-blocker users (n, %) 106 (21.3%) 6.6% 22.9%
Calcium channel blocker users (n, %) 105 (21.1%) 12.5% 21.8%
Nitrate users (n, %) 51 (10.3%) 0% 17.9%
ACE-I/ARB users (n, %) 222 (44.7%) 42.4% 43.4%
Cardiac arrhythmias (n, %) 45 (9.0%) 6.6% 9.2%
Ischemic heart disease (n, %) 134 (30%) 9.3% 28.9%
Dialysis (n, %) 21 (4.8%) 2.9% 3.9%
Hypertension (n, %) 346 (73.8%) 56.8% 69.3%
Chronic obstructive pulmonary disease (n, %) 66 (15.0%) 2.3% 14.6%
Cirrhosis (n, %) 29 (6.5%) 6.8% 5.6%
Alcohol abusers (n, %) 12 (5.3%) 0% 2.7%
Dementia (n, %) 54 (12.3%) 4.6% 11.4%
Cancer (n, %) 63 (14.4%) 4.6% 13.5%
Hospital admission rate (n, %) 184 (35.4%) 5.8% 40.5%
Length of hospital stay (days) 14.7 ± 12.2 4.0 ± 1.0 15.1 ± 12.1
Total mortality (n, %) 12 (2.3%) 0% 2.7%
Sample size, N = 520. Data are expressed as means ± SD, medians and interquartile range (IQR) or absolute and relative proportions. Combination therapy was deﬁned as
the use of insulin plus oral hypoglycemic agents. ACE-I, ACE-inhibitors; ALT, alanine aminotransferase; ARB, angiotensin II receptor blockers; ED, emergency department;
eGFR, estimated glomerular ﬁltration rate; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.
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Alcohol abuse was present in 5.3% of patients. Overall, severe
hypoglycemias requiring extra-familial assistance by the out-of-
hospital emergency services occurred in 74.1% of patients and were
associated with falls at home in 17.6% of cases. A Glasgow Coma
Scale score ≤7was reported in 3.8% of patients. At themedical triage,
the most frequently emergency code assigned was the yellow code
(72.3%), which identiﬁes patients with serious health conditions.
The clinical and biochemical characteristics of patients with di-
abetes stratiﬁed by the three participating EDs are shown in
Supplemental Table S1. Patients attending the ED of Sapienza Uni-
versity had more severe comorbidities (i.e., cirrhosis, cancer,
dementia, ischemic heart disease, chronic obstructive pulmonary
disease) than those attending the EDs of the other two University
hospitals.
As also shown in Table 1, in the whole sample, hospitalization
rates occurred in 35.4% of patients, whereas in-hospital deaths oc-
curred in 2.3% of cases. The average length of hospital stay was
14.7 ± 12.2 days. Interestingly, when patients were stratiﬁed by type
of diabetes, those with type 2 diabetes were older and had a higher
prevalence of main comorbidities (e.g., cardiac arrhythmias, cancer,
dementia, ischemic heart disease, chronic obstructive pulmonary
disease) than patients with type 1 diabetes. Consequently, the hos-
pital admission rate and the length of hospital stay were lower in
patients with type 1 diabetes than in those with type 2 diabetes.
No patients with type 1 diabetes died.
Collectively, 43.6% of patients were treated with oral hypogly-
cemic agents, 42.8% with insulin and 13.6% with combined therapy.
Among patients with type 1 diabetes, only a patient was treated
with insulin pump therapy, whereas all others were treated with
intensive conventional therapy.
When patients with type 2 diabetes were stratiﬁed by age, we
found that 53% of those aged ≥65 years were treated with oral hy-
poglycemic drugs alone, 35% with insulin therapy and the remaining
12% with combined therapy (data not shown). Among those treated
with oral hypoglycemic drugs, we found that the use of sulfonylureas
(i.e., glibenclamide, gliclazide and glimepiride) was similar among
patients older than 65 years and those aged <65 years (84.6% vs.
72.1%, p = 0.24). Conversely, the use of repaglinide was higher in pa-
tients older than ≥65 years compared with those aged <65 years
(27.5% vs. 1.2%, p = 0.02).
Interestingly, as shown in Fig. 2, among patients treated with
a single oral hypoglycemic drug, repaglinide was the most
frequently used drug, followed by metformin, glimepiride,
glibenclamide and gliclazide. In contrast, glibenclamide and
metformin were the two most common used drugs among those
treated with two or three oral hypoglycemic drugs. Overall, among
the oral hypoglycemic drugs, 73.0% were sulfonylureas, and
glibenclamide (54.5%) was the most frequently used sulfonylurea,
followed by glimepiride (11.3%) and gliclazide (7.5%). Repaglinide
was used in 25.7% of these patients.
Fig. 3 shows the frequency of main comorbidities in patients with
type 2 diabetes in relation to the different types of diabetes treat-
ment (i.e., secretagogues alone, insulin, or both). Compared with
those treated with either secretagogues or insulin alone, patients
with type 2 diabetes treated with combined therapy had a higher
prevalence of CKD. Conversely, patients treated with insulin alone
had a higher prevalence of cirrhosis.
Predictors of hospital admission
Table 2 shows the independent predictors of hospital admis-
sion in patients attending the EDs for severe hypoglycemia. Logistic
regression analysis revealed that cirrhosis (OR 6.76, 95% CI 1.24–
36.8, p < 0.05), CKD (OR 2.42, 95% CI 1.11–8.69, p < 0.05) and center
(Sapienza University, OR 3.70, 95% CI 1.57–8.69, p < 0.05) were the
strongest and independent predictors of subsequent admission to
the hospital, whereas the type of diabetes treatment was not. We
also performed separate analyses in patients with type 2 and type
1 diabetes. Similarly, we found that cirrhosis (OR 3.34, 95% CI 1.12–
27.1, p < 0.05), CKD (OR 2.03, 95% CI 1.09–4.20, p < 0.05) and center
(Sapienza University, OR 3.57, 95% CI 1.42–9.02, p < 0.05) were the
strongest predictors of increased hospitalization rates in patients
with type 2 diabetes. Conversely, only cirrhosis (OR 9.14, 95% CI 0.98–
85.3, p = 0.05) was a signiﬁcant predictor of increased hospitalization
rates in patients with type 1 diabetes. However, given the small
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number of patients with type 1 diabetes, these results should be
interpreted with some caution.
Discussion
It is known that the rates of symptomatic hypoglycemia in pa-
tients with established diabetes are relatively high, since nearly 10–
15% of patients with type 1 diabetes have severe hypoglycemia with
seizure or loss of consciousness per year, and, even though less fre-
quently, these events also occur in patients with type 2 diabetes
[1–3,16].
In this multicenter study involving three Italian University hos-
pitals, we identiﬁed a relatively high rate of severe hypoglycemias
(i.e., a total of 520 cases over a period of 4 years) in patients with
established diabetes requiring ED cure. However, since the pa-
tients themselves usually treat most of their mild or moderate
hypoglycemic events without any assistance from another person,
it is important to underline that our results represent only the “tip
of the iceberg” of a serious clinical health problem. Therefore, it is
plausible to assume that our results may largely underestimate the
prevalence of symptomatic hypoglycemias in people with estab-
lished diabetes.
In this multicenter study, we found that most cases of severe
hypoglycemia occurred in older patients with one or more
comorbidities. Our ﬁndings also conﬁrm the results of another recent
Italian multicenter study byMarchesini et al. who showed that older
age, diabetes treatment and the number of comorbidities were the
main predictors of ED admission for severe hypoglycemia [4].
However, some differences existing between these two studies merit
to be discussed. Firstly, we also performed separate analyses in pa-
tients with type 1 and type 2 diabetes. Secondly, we examined the
association of main comorbidities with diabetes treatment (i.e., se-
cretagogues, insulin, or both) in patients with type 2 diabetes, as
we believe that the frequency of comorbidities may vary depend-
ing on diabetes treatment. In fact, we found that patients treated
with insulin plus secretagogues had a greater prevalence of CKD,
whereas those treated with insulin alone had a greater prevalence
of cirrhosis. Thirdly, contrarily to our expectations, we did not observe
any signiﬁcant association between different types of diabetes treat-
ment and risk of hospitalization (although there was a borderline
signiﬁcance for the sulfonylurea drug users).
In this study, the treatment of severe hypoglycemia appeared to
be timely enough to allow a partial or complete resolution of the
acute event, as suggested by the patient’s blood glucose levels above
the threshold of 3.8 mmol/L that were recorded in the ED’s labo-
ratories. However, no complete information was available about the
different types of treatment used to correct hypoglycemic events
both in EDs and out-of-hospital.
Notably, as shown in Table 1, insulin treatment was the most im-
portant drug responsible for severe hypoglycemia, since 56.4% of
patients were treated with insulin, either singly (42.8%) or in com-
bination with oral hypoglycemic drugs (13.6%). Accordingly, a recent
large study performed in older Americans reported that insulin treat-
ment was one of the most important drugs responsible for hospital
admission for any adverse drug events, second only to warfarin use
[17]. Similarly, Geller et al. showed that the rates of ED admission
and subsequent hospitalization for insulin-induced hypoglycemia(s)
were more than twice among patients with 80 years or older than
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among those with 45–64 years, and that almost one-third of insulin-
induced hypoglycemia resulted in subsequent hospitalization [6].
In our study, glibenclamide and repaglinide were found to be the
two oral hypoglycemic agents that were more frequently used by
our patients with type 2 diabetes. According to the ARNO obser-
vatory database, glibenclamide, singly or in combination with
metformin, is widely used in Italy for the treatment of diabetes,
whereas repaglinide is frequently prescribed for older type 2 dia-
betic patients with CKD [18]. However, given the strong ability of
both glibenclamide and repaglinide to increase pancreatic insulin
secretion, these two oral drugs may confer a higher risk of drug-
induced hypoglycemias, especially in older patients with multiple
co-morbidities [19]. Conversely, in our study, a very small number
of patients were treated with either glitazones or incretin-based
therapies. This ﬁnding may largely reﬂect the limited use in Italy
of these newer classes of hypoglycemic drugs during the period
2010–2014, when comparing with metformin and secretagogues,
while being consistent anyhow with existing data that attribute a
(relatively) lower risk of hypoglycemic events to these new hypo-
glycemic drugs. Notably and surprisingly, only 5% of our patients
with type 2 diabetes were treated with metformin alone. It is im-
portant to note that these patients were identiﬁed using the terms
“hypoglycemia” or “hypoglycemic event” in the discharge diagno-
ses from the EDs. Therefore, we are not able to rule out a
misdiagnosis (as it happens quite often in EDs) for those diabetic
patients who go to ED for any acute event of faintness, hypoten-
sion or loss of consciousness from other causes and get a diagnosis
of “hypoglycemia” just because they have diabetes or are treated
with any glucose-lowering agents. However, it cannot be also ex-
cluded that metformin may cause hypoglycemia especially in older
patients withmultiple comorbidities [20]. Interestingly, in our study,
all patients treated with metformin alone had CKD and other severe
comorbidities.
A relatively small number of our patients with severe hypogly-
cemia (17.6%) also reported an increased risk of falls at home. It is
known that insulin treatment is associated with an increased risk
of falls, especially in older patients [21]. Unfortunately, given the
retrospective design of our multicenter study, we were unable to
identify the exact causes or consequences of these falls.
The high prevalence of important comorbidities, such as isch-
emic heart disease, cancer, cirrhosis, dementia and CKD, we observed
in this study, may explain, at least in part, the increased rates of
subsequent hospitalization and the long duration of the hospital stay.
Indeed, as reported in Table 2, cirrhosis and CKDwere the twomost
important comorbidities that drove the hospital admission in our
patients.
Overtreatment or even wrong treatment may be also sug-
gested by the results of our multivariate logistic analyses: advanced
liver and kidney diseases are two clinical pathologic conditions in
which most of oral hypoglycemic drugs are either not indicated or
should be used cautiously. It is well known that serious hypogly-
cemic events may frequently occur in diabetic patients with
decompensated cirrhosis or hepatocellular carcinoma, probably
because of an altered drugmetabolism by the liver [22]. In our study,
the risk of hospital admission associated with cirrhosis was very
high (adjusted OR ~7). This ﬁndingmay be likely due to the fact that,
as reported in Supplemental Table S1, patients with established di-
abetes attending the ED of Sapienza University were quite different
from those of the other two University hospitals, especially in terms
of prevalence of cirrhosis. In addition, diabetes and CKD are two
highly prevalent chronic diseases that frequently coexist in older
people. As known, a reduced kidney function results in accumula-
tion of drugs and/or their metabolites with a subsequent increased
risk of developing serious side effects. In type 2 diabetic patients
treated with sulfonylureas, singly or in combination with insulin,
the presence of CKD signiﬁcantly increases the risk of severe
hypoglycemias [23,24]. Therefore, sulfonylureas should be used cau-
tiously in patients with CKD, and dose adjustment or use of other
hypoglycemic drugs should always be considered [23,24]. More-
over, in patients with CKD the risk of hypoglycemia may be high
even in those treated with insulin, especially if the insulin dose is
not properly adjusted or reduced [23,24].
Surprisingly, in our study, we observed that the type of anti-
diabetic treatment (e.g., insulin vs. oral agents) did not independently
predict an increased rate of hospital admission (although the use
of sulfonylureas alone tended to reach a statistical signiﬁcance).
In our sample the rate of all-cause mortality was similar to that
reported in other recent studies [4]. Of the 12 patients who died,
3 patients died in ED, and 9 patients died during the hospital stay.
It is possible to assume that there is a link between severe hypo-
glycemia and mortality risk in patients with diabetes. For example,
severe and/or recurrent hypoglycemias may precipitate or worsen
a coexisting cardiovascular disease, especially in terms of in-
creased risk of ventricular arrhythmias [25]. Although a number of
other pathophysiological mechanismsmay be also implicated in the
link between severe hypoglycemia and death, however, the retro-
spective design of our study does not allow us to draw any ﬁrm
conclusions on the causes of death in these patients.
Our study has some important limitations that merit to be men-
tioned. Firstly, the cross-sectional and retrospective design of the
study limits our ability tomake any causal inferences. Secondly, blood
glucose concentrations at the time of the hypoglycemic event
and other biochemical parameters (e.g., hemoglobin A1c) were not
Table 2
Main predictors of hospital admission in patients with established diabetes requir-
ing ED care for severe hypoglycemia
Multivariate logistic regression models Odds ratio 95% CI P value
Overall (n = 520)
Age (years) 1.02 0.99–1.06 0.13
Sex (male vs. female) 0.89 0.42–1.87 0.76
Insulin users (yes vs. no) 0.61 0.13–2.81 0.53
Sulfonylurea alone users (yes vs. no) 1.61 0.32–8.02 0.56
Two or more oral glucose-lowering
drug users (yes vs. no)
1.63 0.35–7.62 0.53
Ischemic heart disease (yes vs. no) 1.34 0.61–2.92 0.46
Cirrhosis (yes vs. no) 6.76 1.24–36.8 <0.05
Dementia (yes vs. no) 1.94 0.69–5.45 0.20
Chronic kidney disease (yes vs. no) 2.42 1.11–8.09 <0.05
Sapienza Hospital (yes vs. no) 3.70 1.57–8.69 <0.05
T2DM (n = 444)
Age (years) 1.03 0.98–1.07 0.26
Sex (male vs. female) 1.21 0.53–2.76 0.65
Insulin users (yes vs. no) 1.57 0.69–23.2 0.12
Sulfonylurea alone users (yes vs. no) 5.53 0.87–35.1 0.07
Two or more oral glucose-lowering
drug users (yes vs. no)
4.01 0.69–23.2 0.60
Ischemic heart disease (yes vs. no) 1.88 0.80–4.42 0.15
Cirrhosis (yes vs. no) 3.34 1.12–27.1 <0.05
Dementia (yes vs. no) 1.99 0.68–5.80 0.21
Chronic kidney disease (yes vs. no) 2.03 1.09–4.20 <0.05
Sapienza Hospital (yes vs. no) 3.57 1.42–9.02 <0.05
T1DM (n = 68)
Age (years) 0.93 0.84–1.05 0.25
Sex (male vs. female) 0.52 0.20–1.65 0.09
Ischemic heart disease (yes vs. no) 3.78 0.65–7.23 0.52
Cirrhosis (yes vs. no) 9.14 0.98–85.3 0.05
Chronic kidney disease (yes vs. no) 5.33 0.25–11.7 0.28
Sapienza Hospital (yes vs. no) 10.1 0.38–40.9 0.15
Data are expressed as odds ratios (OR) ± 95 % conﬁdence intervals (CI) as assessed
by multivariable logistic regression analysis. Hospital admission was the depen-
dent variable in all logistic regression models. Chronic kidney disease was deﬁned
as eGFRMDRD <60 mL/min/1.73 m2 and/or dialysis. T1DM, type 1 diabetes mellitus;
T2DM, type 2 diabetes mellitus.
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available in all patients. Thirdly, the data regarding the speciﬁc causes
of death and the risk factors playing a role in the pathogenesis of
severe hypoglycemia and its consequences were not investigated.
Notwithstanding these limitations, our study has important
strengths, including the relatively large sample size, the data anal-
ysis stratiﬁed by type of diabetes and by diabetes treatment, and
the ability to adjust our results for multiple clinical risk factors.
In conclusion, our multicenter study, involving three Universi-
ty hospitals, shows that severe hypoglycemia due to insulin treatment
or oral hypoglycemic drugs (mainly sulfonylureas and repaglinide)
is a dramatic acute event for patients with established diabetes, in-
creasing the risk of adverse clinical outcomes, mostly in elderly and
frail individuals. Our data conﬁrm that insulin treatment is the most
important drug responsible for severe hypoglycemic events. From
a clinical standpoint, we believe that it is essential to provide ad-
equate education for self-monitoring blood glucose levels,
hypoglycemic symptom recognition and its correction as well as for
correct management of pharmacological treatment for diabetes
[26,27]. Moreover, since glibenclamide and repaglinide were the two
most common oral hypoglycemic drugs taken by our patients ad-
mitted with severe hypoglycemia, this study further reinforces the
concept that careful attention should be taken by health care pro-
viders when they prescribe sulfonylureas or repaglinide in elderly
patients with serious comorbidities [28,29]. Moreover, overtreat-
ment should be always avoided in these patients [30]. As also
suggested by recent guidelines, it is important that health care
providers customize glycemic targets and glucose-lowering therapy
after taking into consideration age, medical history and comorbidities
of their patients with diabetes [13,14]. It is likely that the advent
of newer hypoglycemic drugs with a lower risk of drug-induced
hypoglycemia should help to reduce the incidence of severe hypo-
glycemia and its adverse consequences, especially among the more
vulnerable patients.
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